InVivo Therapeutics Appoints Gregory D. Perry as Interim CFO

  InVivo Therapeutics Appoints Gregory D. Perry as Interim CFO

Business Wire

CAMBRIDGE, Mass. -- September 17, 2013

InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a
focus on groundbreaking technologies for thetreatment of spinal cord
injuries(SCI) and neurotrauma conditions, today announced that Gregory D.
Perry has been appointed as interim CFO, commencing September 23, 2013.

Mr. Perry was most recently the Executive Vice President and CFO of Immunogen,
Inc. Prior to joining Immunogen, Mr. Perry served as CFO of Elixir
Pharmaceuticals, Inc. from 2007 to 2009. Prior to Elixir, he was CFO of
Domantis Ltd., which was acquired by GlaxoSmithKline in 2006. Previously, Mr.
Perry was Senior Vice President and CFO of Transkaryotic Therapies, Inc. until
its acquisition by Shire plc in 2005. Mr. Perry is currently a member of the
Board of Directors of Advanced Cell Technology, Inc.

"We are excited tobring on boarda CFO with the integrity, talent and
experience of Greg Perry,” said Mike Astrue, the interim CEO of InVivo. "His
breadth of experience can add value to InVivo in a variety of ways."

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a
platform technology to develop treatments for serious diseases and conditions,
including improving function in individuals paralyzed as a result of traumatic
spinal cord injury. The Company was founded in 2005 on the basis of
proprietary technology co-invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is
affiliated with Massachusetts General Hospital. In 2011, the Company earned
the prestigious David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury medicine.
The publicly traded company is headquartered in Cambridge, MA. For more
details, visit, www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements within the meaning of the
federal securities laws. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to differ
materially from current expectations include, but are not limited to, risks
and uncertainties relating to the Institutional Review Board process, the
Company’s ability to obtain FDA approval to commercialize its products, the
Company’s ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the availability of
substantial additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future product
commercialization; and other risks associated with the Company’s business,
research, product development, regulatory approval, marketing and distribution
plans and strategies identified and described in more detail in our filings
with the SEC, including our Form 10-K and 10-Q’s and our current reports on
Form 8-K. We do not undertake to update these forward-looking statements made
by us.

Contact:

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
bluque@invivotherapeutics.com